Considering whether countries participating in clinical trials can afford the intervention-Reference-Cited by-同舟云学术

Considering whether countries participating in clinical trials can afford the intervention

Published:2022-06-08 Issue:8 Volume:37 Page:1064-1065
ISSN:1460-2237
Container-title:Health Policy and Planning
language:en
Short-container-title:

Author:

Boettiger David Charles¹²³^ORCID,Chattranukulchai Pairoj⁴

Affiliation:

1. Kirby Institute, UNSW Sydney , High Street, Kensington, NSW 2052, Australia

2. Institute for Health and Aging, University of California , 490 Illinois Street, 12th Floor, Box 0646, San Francisco, CA 94158, USA

3. Biostatistics Excellence Centre, Faculty of Medicine, Chulalongkorn University , Phayathai Road, Pathumwan, Bangkok 10330, Thailand

4. Cardiac Center, Faculty of Medicine, Chulalongkorn University, King Chulalongkorn Memorial Hospital , Bangkok, Thailand

Funder

D.C.B

Publisher

Oxford University Press (OUP)

Subject

Health Policy

Link

https://academic.oup.com/heapol/advance-article-pdf/doi/10.1093/heapol/czac044/44263721/czac044.pdf

Reference10 articles.

1. Statins for atherosclerotic cardiovascular disease prevention in people living with HIV in Thailand: a cost-effectiveness analysis;Boettiger;Journal of the International AIDS Society,2020

2. Cardiovascular disease among people living with HIV in Brazil;Boettiger;Tropical Medicine & International Health,2020

3. Cost-effectiveness of statins for primary prevention of atherosclerotic cardiovascular disease among people living with HIV in the United States;Boettiger;Journal of the International AIDS Society,2021

4. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials;Cholesterol Treatment Trialists’ Collaborators;The Lancet,2012

5. Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults (REPRIEVE);ClinicalTrials.gov